巴伐利亚北欧赢得了欧盟关于最多8M剂量天花/天花疫苗的合同,2026年首次交付。 Bavarian Nordic wins EU contract for up to 8M doses of its smallpox/mpox vaccine, with initial delivery in 2026.

巴伐利亚北欧公司获得了欧盟委员会签订的为期四年的合同,向欧盟和其他欧洲国家提供高达800万剂的MVA-BN天花和mopox疫苗,取代了2022年的协议. Bavarian Nordic has won a four-year contract from the European Commission to supply up to 8 million doses of its MVA-BN vaccine for smallpox and mpox to EU and other European countries, replacing a 2022 agreement. 这项交易包括最初的110万剂量,到2026年将交付75万剂量,并允许在疫情爆发期间调整定价和向中低收入国家捐款。 The deal includes an initial 1.1 million doses, with 750,000 to be delivered in 2026, and allows for adjusted pricing and donations to low- and lower-middle-income nations during outbreaks. 多国批准的不复制疫苗对免疫腐蚀的个人来说是安全的。 The non-replicating vaccine, approved in multiple countries, is safe for immunocompromised individuals. 尽管世卫组织不再将天花列为全球紧急情况,但合同在停顿期为10天之前旨在加强区域准备工作。 The contract, pending a 10-day standstill period, aims to strengthen regional preparedness despite the WHO no longer classifying mpox as a global emergency.